Articles On ImpediMed (ASX:IPD)

Bod Australia returns positive results from Phase 1 trial Paradigm and Impedimed make executive changes Creso Pharma no longer the subject of ASIC investigation Cannabis stock Bod Australia (ASX:BOD) announced positive results from its Ph...

ASX health stocks extend weekly gains on Friday as markets rally on back of promising US inflation figures Wound care company Avita rises 24% and biotech Antisense is up 18% for past five days Fertility company Monash IVF provides solid H1...

ImpediMed (IPD) extends its clinical trial contract with AstraZeneca for the third timeThe contract is for further use of IPD’s SOZO digital health platform in a clinical trial being conducted by AstraZeneca on chronic kidney diseaseThe tri...

Pharmaxis completes $10 million capital raise, announces positive interim results for Phase II cancer trial Telix price soars on strong Q1 FY23 results including strong sales of its Illuccix product in US market Impedimed Q1 results in lin...

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...

ShareCafeStocks of the Hour: IPD, EFE, VRC                    ImpediMed (ASX:IPD) this morning announced the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an...

04 Oct 2022 - A snapshot of the stocks on the move featuring ImpediMed (ASX:IPD), Eastern Resources (ASX:EFE) and Volt Resources (ASX:VRC).

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

Monday was not the start to the week that investors were probably hoping for. By the time the closing bell belted out its chime, the S&P/ASX All Ords Index (ASX: XAO) had taken a 2% beating to the downside. Not even the release of ear...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The health sector falls sligh...

Medical software technology company ImpediMed (ASX:IPD) has announced the departure of its managing director and CEO Richard Carreon.

ImpediMed’s (IPD) Managing Director and CEO, Richard Carreon, resigns after a decade with the company Effective by close of business today, Mr Carreon will step down, saying it is the right time to do so with the company “operationally sou...

ImpediMed (IPD) publishes a paper on the risk factors for breast cancer related lymphoedema Key findings of the paper include support for the use of a prospective surveillance model of care, and identifies patients who may benefit from mor...

The ASX will open firmer on Monday  Wall Street little changed on Friday despite strong US non-farms data This week we will see US CPI and China’s GDP data released Local blue chips will open firmer today, with the July ASX 200 futures po...

Gold aspirant Cavalier Resources announces its new substantial shareholders following IPO Gold stocks in demand as investors seek the traditional inflationary hedge Hard hit health and e-commerce stocks continue to lose substantial shareho...

Nordic Nickel announces its new substantial shareholders following its June 2 debut Sigma Healthcare defies ASX health stocks to keep rising and attract new substantial shareholders Hard-hit e-commerce and health stocks among those to lose...

ASX healthcare stocks finish the week modestly in the green Lumos and Audeara rattle the tin in a bid to raise more capital EOFY sell downs puts more pressure on ailing health stocks Healthcare and life sciences expert Scott Power, who ha...

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Look in the mirror and li...

ImpediMed (IPD) has welcomed a second contract extension and expansion of its SOZO Digital Health Platform for use in clinical trials being conducted for AstraZeneca The phase two trial will use the SOZO devices to track patient fluid volu...

In this week’s ScoPo’s Powerplays, healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, examines the turbulent start to 2022 for ASX health stocks and what could lie ahead as ge...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. First a note on things are are...

At the time of writing, the ASX 200 Health Index (XHJ) is down 2%, while the benchmark ASX 200 is also falling by 0.75%. The path is now open for pharma distributor Australian Pharmaceutical Industries (ASX: API) to be acquired by Wesfarmer...

ImpediMed (IPD) announces clinical trial agreement for its SOZO platform, which helps patients with end stage renal disease by assisting with removing fluid during dialysis The company has entered into the agreement with Balboa Research a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Everyone loves a comeback. Just...

ImpediMed (IPD) sees its PREVENT Trial results peer-reviewed and published ImpediMed’s study demonstrated intervention in patients with early detection of cancer-related lymphoedema using its L-Dex technology can result in a lower rate of...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It’s been a...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...

ImpediMed (IPD) completes its share purchase plan, heavily oversubscribed by more than $27 million The share purchase plan (SPP) closed on November 12 and saw applications totalling over $32 million – well in excess of the company’s target...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week With a slew o...

The Impedimed Limited (ASX: IPD) share price has come out of a trading halt today to backtrack mid-afternoon. This comes after the medical technology company provided an update on its recent equity raise. At the time of writing, Impedimed...

The ASX finished in the green by just 0.03%. Today’s gain was spurred by a 1.34% rally in tech shares as well as a rally in Crown (ASX:CWN) shares in the wash-up of the Victorian government’s royal commission. Despite the report finding the...

Market watchers interested in the Impedimed Limited (ASX: IPD) share price have woken to another frosty session as the company’s stock remains frozen for a second day. Impedimed’s shares were halted from trade yesterday while the company u...

The ASX is off to a positive start this week, putting its total gains over the past three weeks up to about 3.6%. The ASX 200 closed 0.34% higher – at 7,441 points. Spurring today’s gains was energy with a 2.64% gain while resources and uti...

ImpediMed is launching a capital raise on Monday morning, on the back of positive clinical trial results last week.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Power says...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

The Impedimed Limited (ASX: IPD) share price is making good ground today, having climbed 10% from the market open to now trade at 16.5 cents. Impedimed shares are again on the move after coming out of a trading halt that was requested bef...

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point in the largest recorded trial to assess lymphoedema prevention The findings were based on a 1,200-person trial over six and a half years, spannin...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Wall Street mixed as ‘debt ceiling’ deadline approaches US stock markets finished in mixed territories on Thursday, as a last session selloff turned the Nasdaq from positive to negative at the close. The Dow Jones rose by 0.26%, the S&P...

The Impedimed Limited (ASX: IPD) share price is on the move during mid-afternoon trade. This comes as the medical technology company announced a positive update in regards to its SOZO Heart Failure Program. At the time of writing, Impedime...

Wall Street mixed to end a volatile week The three US stock marker benchmarks finished the week in mixed territories on Friday, after a volatile week of trading. The Dow Jones rose by 0.1%, S&P 500 by 0.15%, but the tech heavy Nasdaq sl...

Wall Street falls again for fourth consecutive day All three major US stock market benchmarks fell on Friday for the fourth consecutive day. Equity investors are concerned about the rising Delta variant cases, and the impending Fed tapering...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...